Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of HCP1201 vs Metformin + Rosuvastatin in Healthy Volunteers
NCT02011633Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin + metformin in type 2 diabetes mellitus (T2DM) and dyslipidemia (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve to Last Measurable Concentration at 48 hours. Started Oct 2013; status: completed.
02
Drugs
rosuvastatin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT02011633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011633.